Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Entrada Therapeutics (TRDA) Stock Up +4.40% Today?

Why Is Entrada Therapeutics (TRDA) Stock Up +4.40% Today?

Key Takeaways

  • Entrada Therapeutics (TRDA) shares rose 4.40% to $5.22 in afternoon trading on Nov. 17, a gain of $0.22 from the prior close of $5.00.
  • No company press release, SEC filing, clinical update, or analyst action was issued before the move; the advance was not news-driven.
  • The gain came against a weaker tape, with biotech benchmarks and Duchenne muscular dystrophy peers trading lower, pointing to stock-specific buying rather than sector momentum.
  • Secondary drivers include a rebound from a four-month slide, thin liquidity, and short interest of roughly 2.8 million shares, or about 7% of shares outstanding.
  • Volume was light and running well below the stock's roughly 370,000-share daily average, a signature of low-conviction, thin-book trading.
  • News Significance Score: 5/100 — no fresh news met an entirely ordinary 4.40% move for this highly volatile micro-cap.
  • Traders are watching two year-end readouts: Vertex's VX-670 interim data in myotonic dystrophy type 1 and Entrada's own open-label exon 44 data.
  • Investors can dig into Price Targets, Earnings, and Forecast pages for deeper detail on the name.
  • For systematic, rules-based exposure to volatile names like this one, explore Trending AI Robots.

Opening Summary

Entrada Therapeutics, Inc. (TRDA) is a Boston-based clinical-stage biopharmaceutical company developing genetic medicines built on its proprietary endosomal escape vehicle platform. Its pipeline spans Duchenne muscular dystrophy programs targeting exons 44, 45, 50 and 51, an inherited retinal disease candidate, and a partnered myotonic dystrophy type 1 program, VX-670, with Vertex Pharmaceuticals (VRTX).

Shares traded at $5.22 in the final hour of the Nov. 17 session, up $0.22, or 4.40%, from the prior close of $5.00. The direction was unambiguously higher, but the move was not accompanied by any verified company-specific development, leaving market structure and positioning as the most plausible explanations.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found: Entrada issued no press release, filed no material 8-K, and disclosed no clinical or regulatory update ahead of the move, and no analyst rating change or price-target revision was published during the session. The advance therefore appears to be a technical rebound in a thin, micro-cap order book rather than a repricing on new information.

The setup is consistent with mean reversion after a long decline. The stock fell from $5.44 on Nov. 11 to $4.91 at the Nov. 17 open, extending a slide that dates back to the 52-week high of $16.45 and has left it roughly 68% below that level. With a float that trades only a few hundred thousand shares a day, modest buy interest can move the quote several percentage points without any fundamental trigger. Today's move was, in fact, an average day for this name: over the past 69 sessions the stock has moved 4.4% in absolute terms on a typical day, and 27 of those sessions produced a move at least this large.

Positioning: Short Interest and a Depressed Base

Part of the buying may reflect positioning. Short interest stood at roughly 2.81 million shares as of the Oct. 30 settlement date, equal to about 7% of shares outstanding and nearly seven days of average trading volume. In a name this light, even small amounts of covering or speculative dip-buying can produce outsized percentage gains, and the stock's history of double-digit swings on single sessions supports that interpretation.

Durable sentiment also remains soft. Roth MKM trimmed its price target to $10 from $11 on Nov. 5 after October's ENTR-601-45 biomarker data came in below expectations, and H.C. Wainwright reiterated a Hold rating on Nov. 12. The analyst consensus still sits near a Strong Buy with an average target far above the current share price, but recent revisions have leaned cautious, which argues against treating today's bounce as a change in the fundamental narrative.

Market Context and Trading Activity

The move ran counter to the broader tape. The S&P 500 was down roughly 1.3% in afternoon trade, the iShares Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI) were both modestly lower, and Duchenne peers were weaker still, with Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB) falling. Such divergence supports a stock-specific explanation rather than sector sympathy.

Participation was muted. Volume through the afternoon was a fraction of Entrada's roughly 370,000-share average, so the move carried limited conviction. The intraday range of $4.99 to $5.44 showed a strong morning push that faded into the close, and the shares remain below their 50-day average near $5.56 and far from the October low of $4.11, leaving the stock trapped in a broad consolidation band.

News Significance Score

A score of 0 would describe no meaningful news and a move that is routine for the stock; 100 would require transformative news and an extreme, rare price move. Entrada scores 5 out of 100.

The news component was essentially empty: no verified company disclosure, filing, analyst action, or sector catalyst preceded the gain. The price component was equally unremarkable. Today's 4.40% advance matched the stock's typical absolute daily move of roughly 4.4%, and moves of that size or larger occurred 27 times in the last 69 sessions. A routine move on no news combines into a very low score.

What Comes Next for TRDA

The calendar is heavy. Vertex is expected to report interim Phase 1/2 results from the GALILEO study of VX-670 in myotonic dystrophy type 1 before the end of 2026, a readout that could trigger milestone economics under a collaboration carrying $250 million upfront and up to $485 million in milestone payments. Entrada also expects open-label data from Cohort 1 of ELEVATE-44-201 by year-end, followed by Cohort 2 data in the first quarter of 2027 and higher-dose exon 45 data in the first half of 2027. Management has said it expects a second ocular candidate nomination by year-end and will present at the Evercore Healthcare Conference on Dec. 1.

Risks are concentrated and familiar for a clinical-stage issuer. Cash and marketable securities of $193 million are guided to fund operations into the fourth quarter of 2027, but rising DMD trial costs could pressure that runway, and any financing would likely come at depressed levels. Binary trial outcomes, competitive Duchenne data from larger rivals, and the persistent gap between safety signals and dystrophin production remain the central uncertainties.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots page. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to compare approaches side by side. For volatile, news-driven names like this one, reviewing which strategies are currently working can be a useful starting point — take a look at the latest leaders and see how they are positioned.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRDA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TRDA's RSI Oscillator ascends from oversold territory

The RSI Indicator for TRDA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for TRDA just turned positive on October 28, 2026. Looking at past instances where TRDA's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.

Following a +15.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in 262 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where TRDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRDA as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

TRDA broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TRDA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.816) is normal, around the industry mean (3.586). P/E Ratio (-1.235) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. TRDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
One Design Center Place
Phone
+1 857 520-9158
Employees
152
Web
https://www.entradatx.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.